NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HOOK shares have increased by 11.0% and is now trading at $10.27. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hookipa Pharma.

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Hookipa Pharma.

Hookipa Pharma Inc (NASDAQ:HOOK) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.01. The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.36 million. Hookipa Pharma had a negative net margin of 333.02% and a negative return on equity of 36.53%. View Hookipa Pharma's earnings history.

2 analysts have issued 12-month price targets for Hookipa Pharma's shares. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's share price to reach $19.00 in the next year. This suggests a possible upside of 85.0% from the stock's current price. View analysts' price targets for Hookipa Pharma.

Media coverage about HOOK stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hookipa Pharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutHookipa Pharma.

Hookipa Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 202,000 shares, an increase of 17.4% from the April 30th total of 172,100 shares. Based on an average trading volume of 67,200 shares, the days-to-cover ratio is currently 3.0 days. Approximately 1.7% of the shares of the company are sold short. View Hookipa Pharma's Current Options Chain.

Some companies that are related to Hookipa Pharma include ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM), Endo International (ENDP), Amphastar Pharmaceuticals (AMPH), Cue Biopharma (CUE), Gossamer Bio (GOSS), Omeros (OMER), Passage Bio (ORIC), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Kura Oncology (KURA), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP) and Eagle Pharmaceuticals (EGRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Atreca (BCEL), Homology Medicines (FIXX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Stoke Therapeutics (STOK), Akero Therapeutics (AKRO) and Tcr2 Therapeutics (TCRR).

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (8.53%), BlackRock Inc. (2.12%), State Street Corp (0.54%), Geode Capital Management LLC (0.50%), Nuveen Asset Management LLC (0.18%) and Bank of New York Mellon Corp (0.16%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr. View institutional ownership trends for Hookipa Pharma.

HOOK stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Morgan Stanley, UBS Group AG, and First Trust Advisors LP. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky, and Klaus Orlinger. View insider buying and selling activity for Hookipa Pharma.

HOOK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Squarepoint Ops LLC, Howland Capital Management LLC, Russell Investments Group Ltd., Geode Capital Management LLC, and Bank of New York Mellon Corp. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr. View insider buying and selling activity for Hookipa Pharma.

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HOOK stock can currently be purchased for approximately $10.27.

Hookipa Pharma has a market capitalization of $224.19 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

The official website for Hookipa Pharma is www.hookipapharma.com.

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]